- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01651247
Assessment of the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in the Serum of Infants and Toddlers, Following Administration of IPV (Inactivated Poliovirus Vaccine)-Containing Vaccines
July 24, 2012 updated by: GlaxoSmithKline
Blinded Retrospective Laboratory Evaluations to Assess the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in the Serum of Infants Aged 2 and 6 Months and Toddlers Aged 4-6 Years Following Administration of GlaxoSmithKline (GSK) Biologicals' IPV-containing Vaccines
This study aims to analyse the serologic response to PCV-1 in the PEDIARIX® [GSK Biologicals' Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine] and KINRIX® (GSK Biologicals' Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) vaccine products.
The samples have been collected at pre-determined time points from a subset of subjects who participated in selected studies [217744/085 and 213503/048] conducted in the United States.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Serum samples from the previously conducted clinical trials (217744/085 and 213503/048) are used in this study.
Study Type
Observational
Enrollment (Actual)
1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 months to 6 years (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Infants aged 2 and 6 months who were previously given a primary vaccination series consisting of a single dose of combination DTaP-HepB-IPV (PEDIARIX®) vaccine at 2, 4, and 6 months of age or separately administered DTaP (INFANRIX®), HepB (ENGERIX-B®), and IPV (Sanofi-Pasteur's IPOL) vaccines in the study 217744/085 and toddlers aged 4-6 years who were previously vaccinated with a single dose of either the combination DTaP-IPV (KINRIX®) vaccine or separately administered DTaP and IPV vaccines in the study 213503/048.
Description
Inclusion Criteria:
- Subjects enrolled previously in randomized, open and multicentre studies [217744/085; 213503/048].
- Subjects aged 6 months to 6 years at last dose vaccinated with either DTaP-HepB-IPV vaccine or separately administered DTaP, HepB, and IPV vaccines or DTaP-IPV vaccine or separately administered DTaP and IPV vaccines.
- Subjects for whom sufficient residual volume of the pre and post vaccination blood samples is available.
Exclusion Criteria:
- Not Applicable
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group A
Subjects received 3 doses of the combination DTaP-HepB-IPV vaccine or separately administered DTaP, HepB, and IPV vaccines at 2, 4, and 6 months of age, in a previous study (217744/085).
|
Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
|
Group B
Subjects received a single dose of the combination DTaP-IPV vaccine or separately administered DTaP and IPV vaccines at 4-6 years of age, in a previous study (213503/048).
|
Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Presence of serum anti-PCV-1 antibody.
Time Frame: At Day 0 and post vaccination time points (up to 1 month after vaccination).
|
At Day 0 and post vaccination time points (up to 1 month after vaccination).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (Actual)
May 1, 2010
Study Completion (Actual)
May 1, 2010
Study Registration Dates
First Submitted
July 12, 2012
First Submitted That Met QC Criteria
July 24, 2012
First Posted (Estimate)
July 27, 2012
Study Record Updates
Last Update Posted (Estimate)
July 27, 2012
Last Update Submitted That Met QC Criteria
July 24, 2012
Last Verified
July 1, 2012
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 114535
- 213503/048
- 217744/085
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Presence of Materials From PCV-1
-
CerbaXpertNot yet recruitingWoman Suffering From a Pathology Frequently Associated With the Presence of These Anti-autoantibodies Type-I Interferons
-
GlaxoSmithKlineCompletedRotavirus Infection | Evidence of PCV-1 Replication and/or Immune Response to the PCV-1 in HRV Vaccinated Infants
-
NovartisCompletedScreening for the Presence of HIV-1, RNA and HBV DNA in Blood DonationsTaiwan
-
The Hospital for Sick ChildrenUniversity of CalgaryCompletedActively Undergoing Cancer Treatment | 4-9 Years of Age | At Least 1 Month From Diagnosis | Able to Speak and Understand English | Presenting to Clinic for at Least a 2nd Subcutaneous Port Needle InsertionCanada
-
University Hospital, Strasbourg, FranceTerminatedFor Oncologic Patients | Potentially Operable Lung Tumor | With a Recent (Less Than 1 Month) VQ Scan | For Lung Transplant Recipients | Single of Bilateral Lung Transplant | From 5 Months Onwards | With Recent (Less Than 1 Month) Respiratory Functional ExplorationsFrance
-
Yanbing LiNot yet recruitingEfficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients | Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect | 128 Patients Were Randomly Assigned 1:1 | Metformin and Insulin Glargine Combined... and other conditionsChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | High Risk... and other conditionsUnited States
Clinical Trials on Serum sample
-
GlaxoSmithKlineCompletedHepatitis A | Cytomegalovirus | Bordetella Pertussis Infection | Viral Hepatitis Vaccines | Varicella-Zoster Virus | Herpes Simplex (1 and 2)Mexico
-
The Cleveland ClinicCompletedLung Cancer | Biomarkers | Fatty AcidsUnited States
-
Ismail BiyikCompleted
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Azienda Ospedaliera Universitaria Integrata VeronaRecruitingLupus Erythematosus, SystemicItaly
-
ArtialisCompletedUrine Marking | Effects of; SerumBelgium
-
GlaxoSmithKlineCompletedRotavirus Infection | Evidence of PCV-1 Replication and/or Immune Response to the PCV-1 in HRV Vaccinated Infants
-
Assistance Publique Hopitaux De MarseilleUnknownChronic Hemodialysis Patients | Caregivers of Chronic Hemodialysis PatientsFrance
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalCompletedInfertility, Female | Anovulation | Unexplained InfertilityTurkey
-
GlaxoSmithKlineCompleted